Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Aripiprazole for Risperidone-Induced Hyperprolactinemia
NCT02013232Unknown
- Sponsor
- Peking University Huilongguan Hospital
- Start
- Feb 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of aripiprazole in hyperprolactinemia (4 arms), sponsored by Peking University Huilongguan Hospital. Primary endpoint: Prolactin level at 8 weeks. Status: unknown.
02
Drugs
aripiprazole
03
Conditions
hyperprolactinemia
Beyond the preview
Go deeper on NCT02013232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013232.